Director – Quantitative Clinical Pharmacology (PK/PD Modeling & Simulation)
Hemab Therapeutics2 days ago
Highlight
RemoteFull-timeDirector
Summary
Hemab Therapeutics is seeking a Director – Quantitative Clinical Pharmacology (PK/PD Modeling & Simulation) to join their QCP team, providing hands-on leadership in PK/PD modeling and simulation across development programs.
About the Role
As a Director – Quantitative Clinical Pharmacology, you will lead the design, development, and application of population PK, PK/PD, and exposure–response models. Your responsibilities include driving model-informed drug development strategies, performing simulations for clinical studies, analyzing PK/PD data, and contributing to regulatory submissions. You will also provide technical oversight of modeling deliverables and help shape best practices within the organization.
About You
Required:
- Ph.D. in Pharmacometrics, Clinical Pharmacology, Pharmacokinetics, Applied Mathematics, Statistics, or related discipline; or M.S. with substantial relevant industry experience.
- Significant hands-on experience in population PK/PD modeling and simulation within a biotech or pharmaceutical development environment.
- Deep expertise in NONMEM, Monolix, Phoenix NLME, and quantitative programming tools (e.g., R).
- Demonstrated experience contributing to regulatory submissions and interactions involving modeling and simulation.
Preferred:
- Strong understanding of biologics development and translational PK/PD principles; rare disease experience is a plus.
- Ability to clearly communicate complex quantitative concepts to non-quantitative stakeholders.
- Thrives in a fast-paced, collaborative biotech environment with a hands-on, ownership mindset.
Benefits
- Director-level technical ownership without people-management burden.
- High scientific visibility and real influence on development decisions.
- Opportunity to shape modeling strategy in a rare disease biotech.
- Flexible, remote-friendly U.S. role.
Hemab Therapeutics
Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, Massachusetts and Copenhagen, Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance, Hemab 1-2-5, targets the development of 5 clinical assets by 2025 to deliver long-awaited innovation for patients with high unmet need blood clotting disorders like Glanzmann Thrombasthenia, factor VII deficiency, Bernard Soulier Syndrome, Von Willebrand Disease and other serious disorders. Learn more at hemab.com.
Cambridge, MA